- Home
- BRNS vs ANVS Comparison
BRNS vs ANVS Comparison
Compare BRNS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- ANVS
- Stock Information
- Founded
- BRNS 2016
- ANVS 2008
- Country
- BRNS United Kingdom
- ANVS United States
- Employees
- BRNS N/A
- ANVS N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- ANVS Health Care
- Exchange
- BRNS Nasdaq
- ANVS Nasdaq
- Market Cap
- BRNS 28.2M
- ANVS 24.2M
- IPO Year
- BRNS 2021
- ANVS 2020
- Fundamental
- Price
- BRNS $0.84
- ANVS $1.60
- Analyst Decision
- BRNS Strong Buy
- ANVS Strong Buy
- Analyst Count
- BRNS 2
- ANVS 5
- Target Price
- BRNS $3.00
- ANVS $37.00
- AVG Volume (30 Days)
- BRNS 25.3K
- ANVS 448.6K
- Earning Date
- BRNS 05-12-2025
- ANVS 05-12-2025
- Dividend Yield
- BRNS N/A
- ANVS N/A
- EPS Growth
- BRNS N/A
- ANVS N/A
- EPS
- BRNS N/A
- ANVS N/A
- Revenue
- BRNS $14,969,000.00
- ANVS N/A
- Revenue This Year
- BRNS N/A
- ANVS N/A
- Revenue Next Year
- BRNS N/A
- ANVS N/A
- P/E Ratio
- BRNS N/A
- ANVS N/A
- Revenue Growth
- BRNS 1766.46
- ANVS N/A
- 52 Week Low
- BRNS $0.64
- ANVS $1.11
- 52 Week High
- BRNS $2.60
- ANVS $20.00
- Technical
- Relative Strength Index (RSI)
- BRNS 51.29
- ANVS 47.94
- Support Level
- BRNS $0.68
- ANVS $1.19
- Resistance Level
- BRNS $0.97
- ANVS $1.62
- Average True Range (ATR)
- BRNS 0.08
- ANVS 0.15
- MACD
- BRNS 0.02
- ANVS 0.06
- Stochastic Oscillator
- BRNS 55.69
- ANVS 65.08
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.